EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AKR1B1 Expression in the Colorectal Tumor Microenvironment Contributes Towards Its Prognostic Significance

Seçil Demirkol Canlı iD, Güneş Güner, Aynur Işık iD, Branka Sosic-Jurjevi, Aleksandra Djikic Rom, Esin Gülce Seza iD, Ömer Dizdar, Sandra Dragicevic, Aleksandra Nikolic, Aytekin Akyol, Sreeparna Banerjee iD

Cancer Medicine · 2025-05 · 14 (10)

DOI: 10.1002/cam4.70974 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 21.05.2025. Verfasst von Seçil Demirkol Canlı und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Tumor Pathology, Department of Clinical Oncology, Cancer Institute, Hacettepe University, Ankara, Turkiye. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Tumor Microenvironment, Biomarkers, Tumor, Aldehyde Reductase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Türkiye Bilimsel ve Teknolojik Araştırma Kurumu, ODTÜ BAP, Technological Development and Innovations of the Republic of Serbia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

AKR1B1, a member of the aldo‐keto reductase enzyme family involved in the polyol pathway of aldehyde metabolism, is aberrantly expressed in colorectal cancer (CRC). Our previous studies demonstrated that AKR1B1 knockdown reduced the motility and proliferation of CRC cell lines, and its elevated expression was correlated with increased mesenchymal marker expression, inflammation, and poor prognosis in CRC patient cohorts. However, whether stromal cells also express AKR1B1 and whether stromal expression can affect clinical outcomes has not been examined.

Objectives

To evaluate the expression of AKR1B1 within the tumor microenvironment (TME) of CRC, with a paticular focus on stromal cells, and to assess its association with clinical outcomes.

Methods

We assessed AKR1B1 expression in colorectal tumors utilizing publicly available transcriptomic data from CRC tumors. Single‐cell RNA‐sequencing data from CRC samples were analyzed to determine cell type‐specific expression. Immunohistochemistry based assessment of AKR1B1 expression was performed in Turkish and Serbian cohorts. Co‐localization of AKR1B1 and CD163 (M2 macrophage marker) was evaluated by immunoflourescence.

Results

AKR1B1 was expressed in both the epithelial and stromal components of colorectal tumors, with higher expression observed in the stroma. Single‐cell transcriptomic analysis revealed AKR1B1 expression in myeloid cells, T and NK cells, B cells, dendritic cells, fibroblasts, and epithelial cells. Notably, AKR1B1‐expressing macrophages were predominantly of the M2 phenotype, and AKR1B1 expression and M2 marker expression showed strong positive correlation in bulk transcriptomic data. Immunofluorescence confirmed the colocalization of CD163 and AKR1B1 in stromal macrophages. Moreover, immunohistochemical analysis of AKR1B1 expression in tumor stroma from a cohort of Turkish patients revealed that its expression was associated with favorable overall survival, particularly in tumors with higher stromal infiltration.

Conclusions

Overall, our findings underscore the significant influence of the TME composition on the relationship between AKR1B1 expression and clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsTumor MicroenvironmentBiomarkers, TumorAldehyde ReductaseHumansPrognosisFemaleMaleCD163 AntigenAntigens, Differentiation, MyelomonocyticMiddle AgedGene Expression Regulation, NeoplasticReceptors, Cell SurfaceAntigens, CDStromal CellsAged

Stichwörter der Autor:innen

AKR1B1colorectal cancergene expressionprognosisstromatissue microenvironment

Substanzen

AKR1B1 protein, humanBiomarkers, TumorCD163 AntigenAntigens, Differentiation, MyelomonocyticReceptors, Cell SurfaceAntigens, CDAldehyde Reductase

Autor:innen und Institutionen

  • Division of Tumor Pathology, Department of Clinical Oncology, Cancer Institute, Hacettepe University, Ankara, Turkiye.
  • Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkiye.
  • Transgenic Animal Technologies Research and Application Center, Hacettepe University, Ankara, Turkiye.
  • Department of Cytology, Institute for Biological Research "Siniša Stanković"-National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia.
  • Department of Pathology, Pathohistology and Medical Cytology, University Clinical Center of Serbia, Belgrade, Serbia.
  • Department of Biological Sciences, Orta Dogu Teknik Universitesi, Ankara, Turkiye.

ORCID-Profile: Seçil Demirkol Canlı, Aynur Işık, Esin Gülce Seza, Sreeparna Banerjee

Förderung

  • Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
  • ODTÜ BAP
  • Technological Development and Innovations of the Republic of Serbia

Zitieren

APA

Demirkol Canlı, S., Güner, G., Işık, A., Sosic-Jurjevi, B., Rom, A. D., Seza, E. G., Dizdar, Ö., Dragicevic, S., Nikolic, A., Akyol, A., & Banerjee, S. (2025). AKR1B1 Expression in the Colorectal Tumor Microenvironment Contributes Towards Its Prognostic Significance. Cancer Medicine, 14(10). https://doi.org/10.1002/cam4.70974

Vancouver

Demirkol Canlı S, Güner G, Işık A, Sosic-Jurjevi B, Rom AD, Seza EG, et al. AKR1B1 Expression in the Colorectal Tumor Microenvironment Contributes Towards Its Prognostic Significance. Cancer Medicine. 2025;14(10). doi:10.1002/cam4.70974

BibTeX
@article{DemirkolCanl2025,
  author = {Demirkol Canlı, Seçil and Güner, Güneş and Işık, Aynur and Sosic-Jurjevi, Branka and Rom, Aleksandra Djikic and Seza, Esin Gülce and Dizdar, Ömer and Dragicevic, Sandra and Nikolic, Aleksandra and Akyol, Aytekin and Banerjee, Sreeparna},
  title = {AKR1B1 Expression in the Colorectal Tumor Microenvironment Contributes Towards Its Prognostic Significance},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {10},
  doi = {10.1002/cam4.70974}
}
Kostenlos starten →